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Abstract
Background: Basolateral amygdala (BLA) excitatory projections to medial prefrontal cortex (PFC) play a key role controlling 
stress behavior, pain, and fear. Indeed, stressful events block synaptic plasticity at the BLA-PFC circuit. The stress responses 
involve the action of corticotrophin releasing factor (CRF) through type 1 and type 2 CRF receptors (CRF1 and CRF2). 
Interestingly, it has been described that dopamine receptor 1 (D1R) and CRF peptide have a modulatory role of BLA-PFC 
transmission. However, the participation of CRF1 and CRF2 receptors in BLA-PFC synaptic transmission still is unclear.
Methods: We used in vivo microdialysis to determine dopamine and glutamate (GLU) extracellular levels in PFC after BLA 
stimulation. Immunofluorescence anatomical studies in rat PFC synaptosomes devoid of postsynaptic elements were 
performed to determine the presence of D1R and CRF2 receptors in synaptical nerve endings.
Results: Here, we provide direct evidence of the opposite role that CRF receptors exert over dopamine extracellular levels in the 
PFC. We also show that D1R colocalizes with CRF2 receptors in PFC nerve terminals. Intra-PFC infusion of antisauvagine-30, 
a CRF2 receptor antagonist, increased PFC GLU extracellular levels induced by BLA activation. Interestingly, the increase in 
GLU release observed in the presence of antisauvagine-30 was significantly reduced by incubation with SCH23390, a D1R 
antagonist.
Conclusion: PFC CRF2 receptor unmasks D1R effect over glutamatergic transmission of the BLA-PFC circuit. Overall, CRF2 
receptor emerges as a new modulator of BLA to PFC glutamatergic transmission, thus playing a potential role in emotional 
disorders.
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Introduction
The medial prefrontal cortex (PFC) is the main brain area that 
processes information about cognition, motivation, and emo-
tion (Miller and Cohen, 2001). The basolateral nucleus of the 
amygdala (BLA) is a key component of the network that regu-
lates PFC to process emotional information, such as stressful 
stimuli or fear (Sotres-Bayon and Quirk, 2010; Courtin et  al., 
2013). Stressful stimuli constitute an important factor in the 
animal behavior that modifies PFC function (Snyder et al., 2015; 
Urban and Valentino, 2017). Interestingly, it has been shown that 
acute stress exposure blocks BLA-to-PFC synaptic plasticity by 
an unknown mechanism (Maroun and Richter-Levin, 2003). The 
corticotrophin releasing factor (CRF) system integrates both the 
endocrine and behavioral responses to stress (Vale et al., 1981; 
Henckens et al., 2016). The CRF system has 2 G protein-coupled 
receptors, CRF1 and CRF2, which control the cellular excitability 
and synaptic plasticity in some brain areas (Liu et al., 2004, 2005; 
Orozco-Cabal et  al., 2008), including PFC (Millan et  al., 1986; 
Yan et al., 1998; Grammatopoulos et al., 2001; Guan et al., 2014). 
While the role of CRF1 receptor in PFC is well known (Uribe-
Mariño et  al., 2016), the function of CRF2 receptor in the PFC 
has been involved in the modulation of BLA glutamatergic input 
to PFC (Yarur et  al., 2020b). On the other hand, the dopamin-
ergic system mediates the relevance of reward-related stimuli 
(Berridge, 2007). Dopamine (DA) exerts a modulatory influence 
over BLA-PFC synaptic transmission (Floresco and Tse, 2007). 
Remarkably, DA modulates the activity of PFC neurons via dif-
ferent receptor subtypes (Gao et al., 2001; Seamans et al., 2001; 
Tseng and O’Donnell, 2004). It has also been shown that CRF po-
tentiates the modulation exerted by DA on the excitatory trans-
mission of the BLA-to-PFC pathway (Orozco-Cabal et al., 2008).
Together, this evidence prompted us to hypothesize that pre-
synaptic CRF2 receptor modulates the BLA-PFC transmission. To 
address this question, we first assessed CRF2 and DA receptors 
co-distribution in PFC synaptic terminals and then measured 
the impact of CRF2 receptor function in DA and glutamate (GLU) 
release associated with the BLA-PFC transmission. Indeed, we 
demonstrated that CRF2 receptors co-distributed with D1Rs in 
PFC nerve terminals and that its blockade reduced DA and in-
creases GLU release in PFC by BLA activation. Interestingly, PFC 
treatment with a D1R antagonist precluded the CRF2 receptor 
blockade-dependent GLU release. Overall, our results showed 
that CRF2 receptor in PFC nerve terminals play a key role in 
regulating the BLA-PFC glutamatergic transmission needed for 
connecting emotional stress and decision-making control.
Materials and Methods
Animals
Male Sprague-Dawley rats (270–300 g) with ad libitum food and 
water were used throughout this study. Rats were obtained 
from the UC CINBIOT Animal Facility of Pontificia Universidad 
Católica de Chile. The experimental protocols were approved by 
the Institutional Bioethical Committee of Pontificia Universidad 
Católica de Chile.
Preparation of PFC Synaptosomes
Purified synaptosomes of PFC, devoid of postsynaptic density, 
were prepared on a discontinuous Percoll gradient as described 
(Rodrigues et al., 2005; Ciruela et al., 2006; Yarur et al., 2020b). 
The PFC was dissected out of coronal slices of 4 animals fol-
lowing the Atlas of Paxinos and Watson (1986). The extracted 
tissue was placed in a glass Potter homogenizer with 10 mM 
HEPES, 320 mM sucrose, and 3 mM EDTA, pH 7.4, and centri-
fuged at 1000 × g for 10 minutes at 4°C. The supernatant was 
centrifuged at 17 000 × g for 20 minutes at 4°C. The obtained 
pellet was resuspended and centrifuged in a Percoll gradient 
(PVP-silica colloid, Sigma Aldrich, St Louis, MO) at 15 000 × g for 
20 minutes at 4°C. The synaptosomal fraction was dissolved (in 
an equal volume to the fraction obtained) in 320 mM sucrose 
solution for immunofluorescence or radioimmunoprecipitation 
assay lysis buffer (Millipore) solution for western blotting. The 
synaptosomal protein concentration was determined by Micro 
BCA Protein Assay Kit (Thermo Fisher).
Immunofluorescence in PFC Synaptosomes
Immunofluorescence in synaptosomes was performed as pre-
viously described (Ciruela et  al., 2006; Yarur et  al., 2020b). 
Synaptosomes from PFC (15 μg of synaptosomal protein) were 
seeded on coverslips coated with poly-L-lysine (Sigma Aldrich) 
and fixed with 4% paraformaldehyde/10 % sucrose for 15 min-
utes, permeabilized with 0.2% Triton X-100, and incubated for 
1 hour with blocking solution (4% bovine serum albumin in 
phosphate buffered saline). The synaptosomes were incubated 
1 hour at room temperature with the primary antibodies rabbit 
anti-D1R (1:500; ab20066, Abcam), goat anti-CRF2 receptor (1:500; 
SC-1826; Santa Cruz Biotechnology), and mouse anti-D2R (1:500; 
Santa Cruz Biotechnology, Dallas, TX), and thereafter for 1 hour 
with the corresponding secondary antibodies (donkey anti-goat 
Alexa fluor-488, donkey anti-mouse Alexa fluor-594, and donkey 
anti-rabbit Alexa fluor-555; 1:200; Invitrogen). The images 
were captured with a 100× objective in a confocal microscope 
(Olympus, Fluoview 1000)  and analyzed with FLUOVIEW v6.0 
software. Each synaptosomal preparation was obtained from 4 
animals, and photographs for quantification were taken with 
60× from 8 different subareas in each coverslip and processed 
by ImageJ software (rsb.info.nih.gov/ij).
In Vivo Microdialysis
Animals were anesthetized with 8% chloral hydrate (400 mg/kg, 
i.p.) and placed in a stereotaxic apparatus. Body temperature was 
maintained at 37°C by an electrical blanket, and chloral hydrate 
Significance Statement
Corticotrophin-releasing factor (CRF), through its action on CRF type 1 and CRF type 2 receptors, and dopamine (DA), through DA 
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was maintained at 0.8  µL/min by an electrical infusion pump 
(Bioanalytical systems inc). A microdialysis probe (2 mm length; 
MAB 2.14.2, Microbiotech) was implanted in PFC (AP = 3.2  mm, 
ML = 0.7  mm, and DV = 5.0  mm from Bregma), and a second 
microdialysis probe (CMA 11, CMA Microdialysis AB) was im-
planted in the BLA (AP = 2.8 mm, ML = 4.8 mm, and DV = 8.2 mm 
from Bregma). The microdialysis protocol used was previously de-
scribed (Vega et al., 2018). Artificial cerebrospinal fluid (aCSF) was 
perfused through the microdialysis probes at 2 µL/min. After the 
stabilization period (90 minutes), samples were collected every 
10 minutes from the PFC. At the time indicated, 70 mM K+-aCSF 
was perfused through the microdialysis probe in the BLA for 10 
minutes. Antisauvagine-30 (1 µM, Tocris), CP154526 (1 µM, Tocris), 
Raclopride (0.1 µM, Tocris), or SCH23390 (1 µM, Tocris) was perfused 
intra-PFC, as indicated in the figures, and the drug concentrations 
used were as previously described (Orozco-Cabal et al., 2008; Yarur 
et al., 2020b). All drugs were diluted in aCSF containing 0.1 mg/mL 
bovine serum albumin. After the experiments, the brains were re-
moved and stored in 4% paraformaldehyde for verification of the 
microdialysis probe placements. DQuantification of GLU and DA 
was performed using high performance liquid chromatography-
fluorometric determination for GLU and high performance liquid 
chromatography-electrochemical determination for DA, as previ-
ously described (Sotomayor-Zarate et al., 2010).
Statistical Analyses
Statistical analyses were performed with the statistical soft-
ware GraphPad Prism 6 (GraphPad Software). The data are ex-
pressed as the mean ± SEM. Microdialysis experiments were 
analyzed with 2-way ANOVA followed by Bonferroni’s multiple 
comparisons test. The percentage of change was calculated 
using the average values from time point 70 minutes (K+ stimu-
lation period) with respect to the 10 minutes before K+ stimula-
tion onset and were analyzed with 1-way ANOVA followed by 
Dunnett’s multiple comparison test.
Results
CRF Receptors Modulate Extracellular DA Levels 
in PFC
Considering the modulatory role of CRF over the DA tone on 
the BLA-PFC synapses (Orozco-Cabal et al., 2008), we evaluated 
how CRF receptor blockade modulates DA release in PFC. To this 
end, we assessed PFC DA extracellular levels by microdialysis on 
BLA stimulation in the absence or presence of local probe infu-
sion of CRF receptor antagonists (aSvg30 for CRF2 receptor and 
CP154,526 for CRF1 receptor) (Fig. 1). Interestingly, the infusion 
of CP154,526 in PFC significantly increased PFC DA extracellular 
levels (Fig.  1B). On the other hand, aSvg30 decreased PFC DA 
extracellular levels (Fig.  1B). Two-way ANOVA revealed a main 
effect of treatment (F2,6 = 74.16, P < .0001), time (F9,27 = 102.4, 
P < .0001), and a treatment × time interaction (F18,54 = 16.84, 
P < .0001); (****P < .00001, ***P < .0001, **P < .001, *P < .05 vs aCSF, 
Dunnett post-hoc test). BLA stimulation induced PFC DA re-
lease in the presence of both CRF receptor antagonists (Fig. 1B). 
Interestingly, we found that the magnitude of change in DA 
levels between the stimulation and pre-stimulation time was af-
fected only in the presence of aSvg30 (Fig. 1C). One-way ANOVA 
revealed a main effect in the reduction induced by BLA stimula-
tion in the aSvg30 group (***P < .0001 vs aCSF, Dunnett post-hoc 
test; F2,9 = 17.49, P = .0008), suggesting a modulation by CRF2 re-
ceptor of PFC DA extracellular levels induced by BLA stimula-
tion. Overall, these results suggest that CRF1 and CRF2 receptors 
modulate PFC DA extracellular levels, but only CRF2 receptor 
modulates DA extracellular levels induced by the BLA activity.
CRF2 and DA Receptors Co-distribute in PFC 
Synaptic Terminals
Considering that CRF2 receptor modulates BLA-dependent 
PFC DA release, we interrogated whether CRF2 and DA recep-
tors co-distribute in a synaptosomal preparation devoid of 
Figure 1. PFC infusion of the CRF antagonists modulates the extracellular DA levels in PFC. (A) Brain coronal sections showing the placement of the microdialysis 
probes in BLA (−3.1 mm to −3.3 mm from bregma) (bottom) and PFC (3.7 mm to 3.2 mm from bregma) (top). (B) In vivo measurement of PFC extracellular DA levels 
using in vivo microdialysis. The vertical gray bar indicates the time of BLA perfusion with 70 mM K+-aCSF, and the horizontal black line indicates the time of intra-PFC 
infusion of the antagonists. Intra-PFC extracellular DA levels in the presence of aCSF (n = 4), 1 µM aSvg30, CRF2 antagonist (n = 4), and 1 µM CP154,526, CRF1 receptor 
antagonist (CP154, n = 4). Values correspond to the -fold of the mean of the first 3 basal values for each condition. (C) Effects of aSvg30 and CP154 infusion on BLA-
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postsynaptic elements (Rodrigues et al., 2005). To this end, we 
performed CRF2 receptor immunofluorescence detection in 
PFC synaptosomes enriched in presynaptic elements (Fig.  2). 
Interestingly, CRF2 receptor was found in presynaptic PFC nerve 
terminals co-distributing with D1R (Fig. 2A, C–D). Overall, 79.11% 
± 1.57% of PFC synaptosomes bearing CRF2 receptor were also 
positive for D1R and 23.98% ± 4.45% of PFC synaptosomes posi-
tive for D1R co-expressed CRF2 receptor. At the same time, CRF2 
receptor co-distributed with D2R (Fig. 2B–D). The 64.5% ± 6.72% 
of PFC synaptosomes bearing CRF2 receptor were positive for 
D2R and 73.56% ± 3.4% of PFC synaptosomes positive for D2R 
co-expressed CRF2 receptor. Thus, these results showed that 
CRF2 receptors coexist with D1R and D2R in PFC nerve terminals.
CRF2 and DA Receptors Modulate PFC GLU 
Extracellular Levels
It has been shown that CRF and DA receptors modulate BLA-
evoked excitatory postsynaptic current in PFC (Orozco-Cabal 
et  al. 2008). Thus, we evaluated whether CRF2 and DA recep-
tors may modulate GLU content in PFC. To this end, we deter-
mined GLU levels in PFC on infusion of CRF2 and DA receptor 
antagonists (Fig.  3). Two-way ANOVA revealed a main effect of 
treatment (F3,9 = 29.98, P < .0001), time (F9,27 = 75.51, P < .0001), 
and a treatment × time interaction (F27,81 = 30.83, P < .0001) 
(****P < .00001, ***P < .0001, **P < .001, *P < .05 vs aCSF, Dunnett post-
hoc test). Interestingly, the infusion of aSvg30 in PFC through the 
microdialysis probe significantly increased BLA-induced PFC GLU 
release (Fig.  3B–C). One-way ANOVA revealed a main effect in 
the facilitation induced by BLA stimulation in the aSvg30 group 
(**P < .0001 vs aCSF, Dunnett post-hoc test; F3,12 = 30.57, P < .0001). 
These results suggested that CRF2 receptor negatively regulates 
BLA-induced PFC GLU release. Next, we assessed the effect of PFC 
infusion of SCH23390 (1 µM), a D1R selective antagonist, in BLA-
induced PFC GLU release. The infusion of SCH23390 alone did not 
affect basal and BLA-induced PFC GLU release (Fig. 4). Interestingly, 
the co-infusion of SCH23390 with aSvg30 significantly blocked 
the increase in BLA-induced PFC GLU release (Fig. 3B–C). Next, we 
analyzed the effect of PFC infusion of raclopride (0.1 µM), a D2R 
selective antagonist, in BLA-induced PFC GLU release. Two-way 
ANOVA revealed a main effect of treatment (F2,6 = 4.68, P = .0594), 
time (F9,27 = 13.88, P < .0001), and a treatment × time interaction 
(F18,54 = 7.51, P < .0001) (****P < .00001, **P < .001 vs aCSF, Dunnett 
post-hoc test). Thus, the infusion of raclopride alone did not af-
fect basal and BLA-induced PFC GLU release (Fig. 4). Interestingly, 
the co-infusion of raclopride with aSvg30 blocked the effect of 
the aSvg30 in the increase of the BLA-induced PFC GLU release 
(Fig. 3B–C). Together, it shows us that CRF2 and DA receptors sig-
nificantly modulate GLU levels in the BLA-PFC synapse.
Discussion
In the present study, we addressed the role of CRF receptors con-
trolling extracellular DA levels in the PFC. Indeed, CRF2 receptors 
were able to modulate DA levels in the PFC depending on BLA-
PFC circuit activity. In addition, we revealed the coexpression of 
CRF2 receptor with D2R and D1R in PFC synaptic terminals and 
its functional interaction regulating GLU release in the BLA-PFC 
glutamatergic transmission.
The electrical stimulation of BLA prompts DA release 
from ventral tegmental area (VTA) DAergic projections to PFC 
(Jackson and Moghaddam, 2001). Indeed, we were able to recap 
increments of PFC DA extracellular levels on BLA stimulation 
with a depolarizing solution (Fig.  1). It was previously shown 
that electrical stimulation of the BLA increases PFC DA efflux 
(Jackson and Moghaddam, 2001). The available information 
Figure 2. CRF2 receptor co-distributes with DA receptors in PFC presynaptic terminals. (A–B) Confocal immunodetection of CRF2 receptor in preparation of PFC syn-
aptosomes, devoid of presynaptic elements. (A) Immunofluorescence processed for CRF2 receptor (green) and D1R (red) (scale bar = 2 µm). Arrows depict synapto-
somes colocalizing D1R and CRF2 receptor. (B) Immunofluorescence processed for CRF2 receptor (green) and D2R (red) (scale bar = 2 µm). Arrows depict synaptosomes 
colocalizing D2R and CRF2 receptor. (C) Percentage of colocalization of positive CRF2 synaptosomes with total D1R or D2R positive PFC synaptosomes. (D) Percentage of 
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also shows that afferent projections from PFC to VTA make 
direct connection with dopaminergic neurons, which in turn 
project back to the PFC (Carr and Sesack, 2000; Lammel et al., 
2011, 2012). Thus, BLA can increase PFC DA extracellular levels 
through a reciprocal interaction with BLA-PFC-VTA (Jackson 
and Moghaddam, 2004).
CRF receptors are differentially expressed in the brain 
(Henckens et  al., 2016). Thus, while CRF1 receptors are ex-
pressed and function in PFC (Van Pett et al., 2000; Uribe-Mariño 
et  al., 2016), CRF2 receptor expression has been described in 
glutamatergic nerve terminals of the lateral septum (Liu et al., 
2004, 2005) and in VTA GABAergic interneurons (Williams et al., 
2014). We recently described the expression of CRF2 receptors 
in PFC synaptic terminals originated in BLA (Yarur et al., 2020b) 
where they co-distribute with both D1R and D2R (Fig.  2) yet 
show the highest co-distribution with D2R compared with D1R 
(74% vs 24%, respectively). Interestingly, our results suggest an 
additional mechanism of functional interplay between DA and 
CRF2 receptors in PFC synaptic terminals.
CRF1 and CRF2 receptors control neurotransmitter release, 
for instance DA, in different brain areas (Isogawa et  al., 2000; 
Orozco-Cabal et al., 2006; Wang et al., 2007; Lemos et al., 2012; 
Boyson et al., 2014). Here, we unravel the differential contribu-
tion of each CRF receptor controlling DA levels in PFC. Herein, 
CRF1 receptors have a local inhibitory role over PFC extracellular 
DA levels that does not depend on BLA stimulation (Fig. 1B–C) in 
contrast to what was previously reported (Isogawa et al., 2000). 
Importantly, while these authors assessed the role of CRF1 re-
ceptor on systemic (i.p.) antagonist administration, we locally 
administered the CRF1 receptor antagonist. Conversely, local in-
fusion of a CRF2 receptor antagonist significantly reduces PFC 
DA extracellular levels depending on BLA stimulation (Fig. 1B–C). 
Overall, our data show that CRF1 and CRF2 receptors exert op-
posite effects on basal PFC DA extracellular levels, whereas CRF2 
receptor may also exert additional effects on PFC DA extracel-
lular levels that depend on BLA stimulation.
BLA projections into PFC are predominantly glutamatergic 
(Gabbott et al., 2006) with CRF and DA modulating BLA-to-PFC 
Figure 3. PFC infusion of the CRF2 receptor antagonist aSvg-30 (aSvg30) enhanced BLA-induced extracellular GLU increase in PFC but depends of DA receptors. (A) Brain 
coronal sections showing the placement of the microdialysis probes in BLA (−3.1 mm to −3.3 mm from bregma) (bottom) and PFC (3.7 mm to 3.2 mm from bregma) 
(top). (B) In vivo measurement of PFC extracellular GLU levels using in vivo microdialysis. The vertical gray bar indicates the time of BLA perfusion with 70 mM K+-aCSF, 
and the horizontal black line indicates the time of intra-PFC infusion of the antagonists. Intra-PFC extracellular GLU levels in the presence of aCSF (n = 4), 1 µM aSvg30 
(n = 4), 1 µM SCH23390 (SCH, n = 4), and 0.1 µM raclopride (Raclo, n = 4). Values correspond to the -fold of the mean of the first 3 basal values for each condition. For the 
effects of DA receptor antagonist and aSvg30 infusion on BLA-induced PFC extracellular GLU levels, the average values were calculated from time point 70 minutes (K+ 
stimulation period) with respect to 10 minutes before K+ stimulation onset.
Figure 4. PFC infusion of the DA antagonists did not modulate the extracellular GLU levels in PFC dependent of the BLA stimulation. (A) Brain coronal sections showing 
the placement of the microdialysis probes in BLA (−3.1 mm to −3.3 mm from bregma) (bottom) and PFC (3.7 mm to 3.2 mm from bregma) (top). (B) In vivo measurement 
of PFC extracellular GLU levels using in vivo microdialysis. The vertical gray bar indicates the time of BLA perfusion with 70 mM K+-aCSF, and the horizontal black line 
indicates the time of intra-PFC infusion of the antagonists. Intra-PFC extracellular DA levels in the presence of aCSF (n = 4), 1 µM SCH23390 (n = 4), and 0.1 µM raclopride 
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synapses (Orozco-Cabal et al., 2008). Under basal conditions, BLA 
stimulation did not significantly increase PFC GLU levels (Fig. 3). 
It has been described that GLU transmission is more tightly regu-
lated by reuptake or feedforward inhibition in the PFC by BLA 
synaptic terminals (Tejeda et al., 2013; McGarry and Carter, 2016), 
precluding detection with microdialysis. Herein, we described 
that CRF2 receptor modulation of PFC GLU levels depends on 
BLA stimulation (Fig. 3). It should be noted that the microdialysis 
probe placement includes all mPFC regions (prelimbic and 
infralimbic regions), which suggest that CRF2 regulation of DA 
and GLU levels is throughout the mPFC regions. Thus, this BLA-
dependent regulation of GLU content by CRF2 receptor is modu-
lated by D1R and D2R locally in the PFC (Fig. 3). Interestingly, DA 
antagonists alone did not modify PFC GLU extracellular levels 
that depend on BLA stimulation (Fig. 4). Hence, the modulatory 
role of DA receptors was apparent only in the presence of the 
CRF2 receptor antagonist (Fig.  3). Interestingly, it appears that 
the functional interaction between CRF2 receptor and D1R or 
D2R has different levels. First, the co-infusion of the CRF2 re-
ceptor plus the D2R antagonist in the PFC precluded the CRF2 
receptor antagonist effects over BLA-dependent GLU increase. 
Second, the co-infusion of the CRF2 receptor and D1R antag-
onist in the PFC totally occludes the BLA-dependent GLU in-
crease observed in PFC of control animals (Fig. 3B–C). Our results 
suggested that both dopamine receptors negatively interact to 
block CRF2 modulation over PFC GLU release after BLA activa-
tion. Interestingly, we have described a negative interaction be-
tween CRF2 and D1R in PFC synaptosomes (Yarur et al., 2020a). 
Further studies should address synaptic mechanism of this pos-
sible negative interaction between CRF2 and D2R.
The interaction between CRF receptors and DA receptors in 
the PFC has been previously described (Radulovic et  al., 2000; 
Orozco-Cabal et al., 2008; Yarur et al., 2020b). It has been shown 
that a D1R tone in the PFC attenuates excitatory synaptic trans-
mission in layer V pyramidal neurons (Gao et al., 2001) and that 
PFC stimulation recruits interneurons that inhibit BLA pro-
jecting neurons (Rosenkranz and Grace, 2001). Consistently, 
we did not see BLA-dependent GLU increase in PFC because of 
the inhibitory modulation of PFC over BLA by the reduced D1R 
tone on the PFC by the infusion of the D1R antagonist. It has 
been shown that in the PFC, DA release is regulated at the pre-
synaptic site (Tejeda et al., 2013) and that dopamine release in 
PFC can be modulated at the postsynaptic site as well (Takahata 
and Moghaddam, 1998). Based on the observed co-distribution 
levels of CRF2 and D2R in PFC synaptic terminals, we can postu-
late the existence of a precise CRF2-D2R functional interplay in 
these GLU terminals. On the other hand, it has been described 
that D2R agonist in the PFC attenuates BLA-evoked inhibition of 
PFC neurons (Floresco and Tse, 2007). This could suggest that the 
D2R effect over CRF2-induced increase in PFC GLU after stimu-
lation of BLA could be due to the recruitment of an inhibitory 
component in PFC. We observed an increase of GLU post-BLA 
stimulation induced by D2R antagonist. It has been suggested 
that PFC D2R has an inhibitory action over NMDA-induced re-
sponses in the PFC (Tseng and O’Donnell, 2004; Floresco and Tse, 
2007), which could explain why post-BLA stimulation PFC GLU 
extracellular levels were increased. One remaining question to 
be addressed is whether the presence of a D1R antagonist in the 
PFC would inhibit the BLA and if the recruitment of inhibitory 
components by D2R in the PFC modulates the CRF2 effect in the 
BLA-dependent GLU increase in the PFC.
In summary, we show that CRF receptors modulate PFC DA 
content and that CRF2 receptor–mediated modulation is de-
pendent on BLA stimulation. CRF2 receptor colocalizes with 
D1R and D2R in PFC synaptic terminals, but D2R apparently 
colocalizes more with CRF2 receptor than D1R. Finally, we show 
that PFC GLU levels dependent on BLA stimulation are signifi-
cantly modulated by CRF2 and DA receptors in the PFC. Overall, 
our findings should contribute to a better understanding of how 
CRFergic and dopaminergic systems modulate the BLA-PFC syn-
apses and expand the understanding of CRF-dopamine inter-
actions in PFC, which has been shown to be relevant in some 
pathologies associated with stress (Moghaddam, 2016; Sun et al., 
2019). Further studies should address whether the observed 
interaction between CRF2 and DA receptors in the PFC-BLA syn-
apses, an important pathway and target involved in stress re-
sponse, is involved in the complexity of the role of PFC in the 
interaction between emotional stress and decision-making.
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